Skip Navigation

Mad Money Mail: Ironwood Pharma, Santarus & More

Mad Money with Jim Cramer

Mad Money Mail: Ironwood Pharma, Santarus & More

Ironwood Pharmaceuticals recently launched a drug called Linzess, and the company also reported an EPS loss; and Mad Money host Jim Cramer answers viewers' investment questions.

04:32

Thu, Jan 17 20136:45 PM EST

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

Tesla's big gamble: Full Self-Driving in the wild

Tesla's big gamble: Full Self-Driving in the wild

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

Black-owned businesses still face headwinds in obtaining capital

Black-owned businesses still face headwinds in obtaining capital

Stocks picks for companies with 'boomerang CEOs'

Stocks picks for companies with 'boomerang CEOs'

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

Tesla's big gamble: Full Self-Driving in the wild

Tesla's big gamble: Full Self-Driving in the wild

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

Black-owned businesses still face headwinds in obtaining capital

Black-owned businesses still face headwinds in obtaining capital

Stocks picks for companies with 'boomerang CEOs'

Stocks picks for companies with 'boomerang CEOs'